RenovoRx Inc

For the period ended Dec 31, 2023. Filed Apr 1, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Apr 1, 2024

RNXT$1.18+4.4%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Balance Sheets

(in thousands, except share and per share amounts)

	As of December 31,
	2023	2022
Assets
Current assets:
Cash and cash equivalents	$1,173	$4,391
Short-term marketable securities	-	2,049
Prepaid expenses and other current assets	192	825
Deferred offering costs	101	-
Total assets	$1,466	$7,265
Liabilities, Convertible Preferred Stock and Stockholders’ Equity (Deficit)
Current liabilities:
Accounts payable	$561	$534
Accrued expenses	614	568
Total current liabilities	1,175	1,102
Common stock warrant liability	3,291	-
Total liabilities	$4,466	$1,102
Commitments and contingencies (Note 6)	-	-
Convertible preferred stock and stockholders’ equity (deficit):
Convertible preferred stock, $0.0001 par value; 15,000,000 shares authorized as of December 31, 2023 and 2022, respectively; zero shares issued and outstanding at December 31, 2023 and 2022, respectively	-	-
Common stock, $0.0001 par value, 250,000,000 shares authorized at December 31, 2023, and 2022, respectively; 10,693,580 and 9,097,701 shares issued and outstanding as of December 31, 2023, and 2022, respectively	1	1
Additional paid-in capital	38,404	37,318
Accumulated other comprehensive income	-	17
Accumulated deficit	(41,405)	(31,173)
Total convertible preferred stock and stockholders’ (deficit) equity	(3,000)	6,163
Total liabilities, convertible preferred stock and stockholders’ equity (deficit)	$1,466	$7,265

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.